Sphingolipid metabolism: Sphingoid analogs, sphingolipid activator proteins, and the pathology of the cell

Annals of the New York Academy of Sciences

Volumn 845, Issue , 1998, Pages 139-151

  Sandhoff, K ^a   Kolter, T ^a   Van Echten Deckert, G ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE GM2; GLYCOSPHINGOLIPID; HYDROLASE; OLIGOSACCHARIDE; SPHINGOLIPID; SPHINGOLIPID ACTIVATOR PROTEIN;

CELL CULTURE; CELL STRUCTURE; CEREBELLUM; CONFERENCE PAPER; ENDOCYTOSIS; FIBROBLAST; HUMAN; HUMAN CELL; LIPID METABOLISM; LIPIDOSIS; LYSOSOME; NONHUMAN; PATHOLOGY;

ANIMALIA; MURINAE; SPHINGIODEA;

EID: 0031880987     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1998.tb09667.x     Document Type: Article

References (53)

1. WIEGANDT, H. 1985. Gangliosides. In New Comprehensive Biochemistry, Vol. 10, A. Neuberger and L. L. M. van Deenen, Eds.: 199-260. Elsevier. Amsterdam.
2. HAKOMORI, S. 1981. Glycosphingolipids in cellular interactions, differentiation and oncogenesis. Annu. Rev. Biochem. 50: 733-764.
3. HOLMGREN, J., I. LONNROTH, J.-E. MANSSON & L. SVENNERHOLM. 1975. Interaction of cholera toxin and membrane GM1 ganglioside of small intestine. Proc. Natl. Acad. Sci. USA 72: 2520-2524.
4. MARKWELL, M. A. K., L. SVENNERHOLM & J. C. PAULSON. 1981. Proc. Natl. Acad. Sci. USA 78: 5406-5410.
5. KARLSSON, K.-A. 1989. Animal glycosphingolipids as membrane attachment sites for bacteria. Annu. Rev. Biochem. 58: 309-350.
6. SCHNAAR, R. L. 1991. Glycosphingolipids in cell surface recognition. Glycobiology 1: 477-185.
7. WALZ, G., A. ARUFFO, W. KOLANUS, M. BEVILACQUA & B. SEED. 1990. Recognition by ELAM-1 of the sialyl-Lex determinant on myeloid and tumor cells. Science 250: 1132-1135.
8. PHILLIPS, M. L., E. NUDELMAN, F. C. A. GAETA, M. FEREZ, A. K. SINGHAL, S. HAKOMORI & J. C. PAULSON. 1990. ELAM 1 mediates cell adhesion by recognition of a carbohydrate ligand, Sialyl-Lex. Science 250: 1130-1132.
9. SPIEGEL, S., D. FOSTER & R. KOLESNICK. 1996. Signal transduction through lipid second messengers. Curr. Opin. Cell Biol. 8: 159-167.
10. VAN ECHTEN, G. & K. SANDHOFF. 1993. Ganglioside metabolism. J. Biol. Chem. 268: 5341-5344.
11. ROTHER, J., G. VAN ECHTEN, G. SCHWARZMANN & K. SANDIIOFF. 1992. Dihydroceramide and not sphinganine is desaturated by cultured cells. Biochem. Biophys. Res. Commun. 189: 14-20.
12. VAN ECHTEN, G, R. BIRK, G. BRENNER-WEISS, R. R. SCHMIDT & K. SANDHOFF. 1990. Modulation of sphingolipid biosynthesis in primary cultured neurons by long chain bases. J. Biol. Chem. 265: 9333-9339.
13. MANDON, E. C., G. VAN ECHTEN, R. BIRK, R. R. SCHMIDT & K. SANDHOFF. 1991. Sphingolipid biosynthesis in cultured neurons. Eur. J. Biochem. 198: 667-674.
14. KOLTER, T. & K. SANDHOFF. 1996. Inhibitors of glycosphingolipid biosynthesis. Chem. Soc. Rev. 25: 371-381.
15. VAN ECHTEN-DECKERT, G, A. ZSCHOCHE, T. BAR, R. R. SCHMIDT, A. RATHS, T. HEINEMANN & K. SANDHOFF. 1997. Cis-4-methylsphingosine decreases sphingolipid biosynthesis by specifically interfering with serine palmitoyltransferase activity in primary cultured neurons. J. Biol. Chem. 272: 15825-15833.
16. GRIFFITHS, G. W., B. HOFLACK, K. SIMONS, I. S. MELLMAN & S. KORNFELD. 1988. The mannose-6-phosphate receptor and the biogenesis of lysosomes. Cell 52: 329-341.
17. KOVAL, M. & R. E. PAGANO. 1989. Lipid recycling between the plasma membrane and intracellular compartments: Transport and metabolism of fluorescent sphingomyelin analogues in cultured fibroblasts. J. Cell Biol. 108: 2169-2181.
18. CARLSSON, S. R., J. ROTH, F. PILLER & M. FUKUDA. 1988. Isolation and characterization of human lysosomal membrane glycoproteins, h-lamp-1 and h-lamp-2. J. Biol. Chem. 263: 18911-18919.
19. FÜRST, W. & K. SANDHOFF. 1992. Activator proteins and topology of lysosomal sphingolipid catabolism. Biochim. Biophys. Acta 1126: 1-16.
20. SANDHOFF, K. & T. KOLTER. 1996. Topology of glycosphingolipid degradation. Trends Cell Biol. 6: 98-103.
21. HARZER, K., B. C. PATON & A. POULOS. 1989. Sphingolipid activatorprotein (SAP) deficiency in a 16-week old atypical Gaucher desease patient and his fetal sibling; Biochemical signs of combined sphingolipidoses. Eur. J. Pediatr. 149: 31-39.
22. SCHNABEL, D., M. SCHRODER, W. FURST, A. KLEIN, R. HURWITZ, T. ZENK, J. WEBER, K. HARZER, B. C. PATON, A. POULOS, K. SUZUKI & K. SANDHOFF. 1992. Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene. J. Biol. Chem. 267: 3312-3315.
23. BURKHARDT, J. K., S. HUTTLER, A. KLEIN, W. MÖBIUS, A. HABERMANN, G. GRIFFITHS & K. SANDHOFF. 1997. Accumulation of sphingolipids in SAP-precursor (prosaposin) deficient fibroblasts occurs as intralysosomal membrane structures and can be completely reversed by treatment with human SAP-precursor. Eur. J. Biochem. 73: 10-18.
24. SANDHOFF, K., E. CONZELMANN, E. F. NEUFELD, M. M. KABACK & K. SUZUKI. 1989. The GM2 ganglisidoses. In The Metabolie Basis of Inherited Disease, C. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, Eds.: 1807-1839. McGraw-Hill. New York.
25. GRAVEL, R. A., J. T. R. CLARKE, M. M. KABACK, D. MAHURAN, K. SANDHOFF & K. SUZUKI. 1995. The GM2 ganglisidoses. In The Metabolic and Molecular Basis of Inherited Disease, C. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, Eds.: 2839-2879. McGraw-Hill. New York.
26. SANDIIOFF, K., K. HARZER & W. FURST. 1995. Sphingolipid activator proteins. In The Metabolic and Molecular Basis of Inherited Disease, C. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, Eds.: 2427-2441. McGraw-Hill. New York.
27. MEIER, E. M., G. SCHWARZMANN, W. FÜRST & K. SANDHOFF. 1991. The human GM2 activator protein: A substrate specific cofactor of hexosaminidase A. J. Biol. Chem. 266: 1879-1887.
28. KYTZIA, H.-J. & K. SANDHOFF. 1985. Evidence for two different active sites on human hexosaminidase-Interaction of GM2 activator protein with hexosaminidase A. J. Biol. Chem. 260: 7568-7572.
29. SCHRODER, M., D. SCHNABEL, K. SUZUKI & K. SANDHOFF. 1991. A mutation in the gene of a glycolipid-binding protein (GM2 activator) that causes GM2-gangIiosidosis variant AB. FEES Lett. 290: 1-3.
30. SCHRÖDER, M., D. SCHNABEL, R. HURWITZ, E. YOUNG, K. SUZUKI & K. SANDHOFF. 1993. Molecular genetics of GM2 gangliosidosis AB variant: A novel mutation and expression in BHK cells. Hum. Genet. 92: 437-440.
31. SCHEPERS, U., G. J. GLOMBITZA, T. LEMM, A. HOFFMANN, A. CHABÀS, P. OZAND & K. SANDHOFF. 1996. Molecular analysis of a GM2-activator deficiency in two patients with GM2-gangIiosidosis AB variant. Am. J. Hum. Genet. 59: 1048-1056.
32. KLIMA, H., A. KLEIN, G. VAN ECHTEN, G. SCHWARZMANN, K. SUZUKI & K. SANDHOFF. 1993. Over-expression of a functionally active human GM2-activator protein in Escherichia coli. Biochem. J. 292: 571-576.
33. MEHL, E. & H. JATZKEWITZ. 1964. Eine Cerebrosidsulfatase aus Schweineniere. HoppeSeyler's Z. Physiol. Chem. 339: 260-276.
34. FÜRST, W., J. SCHUBERT, W. MACIILEIDT & K. SANDHOFF. 1990. The complete amino-acid sequences of human ganglioside GM2 activator protein and cerebroside sulfate activator protein. Eur. J. Biochem. 192: 709-714.
35. Li, S. C, S. SONNINO, G. TETTAMANTI & Y. T. Li. 1988. Characterization of a nonspecific activator protein for the enzymatic hydrolysis of glycolipids. J. Biol. Chem. 263: 6588-6591.
36. FUJIBAYASHI, S. & D. A. WENGER. 1986. Biosynthesis of the sulfatide/GMl activator protein (SAP-1) in control and mutant cultured skin fibroblasts. Biochim. Biophys. Acta 875: 554-562.
37. FÜST, W., W. MACIILEIDT & K. SANDHOFF. 1988. The precursor of sulfatide activator protein is processed to three different proteins. Biol. Chem. Hoppe-Seyler 369: 317-328.
38. O'BRIEN, J. S., K. A. KRETZ, W. D'EWJI, D. A. WENGER, F. ESCH & A. L. FLUHARTY. 1988. Coding of two sphingolipid activator proteins (SAP-1 and SAP-2) by same genetic locus. Science 2-41: 1098-1101.
39. NAKANO, T., K. SANDHOFF, J. STÜMPER, H. CHRISTOMANOU & K. SUZUKI. 1989. Structure of full-length cDNA coding for sulfatide activator, a co-beta-glucosidase and two other homologous proteins: Two alternate forms of the sulfatide activator. J. Biochem. 105: 152-154.
40. CHRISTOMANOU, H., A. AIGNESBERG & R. P. LINKE. 1986. Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro -Absence of one of them in a human Gaucher disease variant Biol. Chem. Hoppe Seyler 367: 879-890.
41. SCHNABEL, D., M. SCHRÖDER & K. SANDHOFF. 1991. Mutation in the sphingolipid activator protein 2 in a patient with a variant of Gaucher disease. FEES Lett. 284: 57-59.
42. BRADOVA, V., F. SMID, B. ULRICH-BOTT, W. ROGGENDORF, B. C. PATON & K. HARZER. 1993. Prosaposin deficiency: Further characterization of the sphingolipid activator proteindeficient sibs. Multible glycolipid elevations (including lactosylceramidosis), partial enzyme deficiencies and ultrastructure of the skin in this generalized sphingolipid storage disease. Hum. Genet. 92: 143-152.
43. KLEIN, A., M. HENSELER, C. KLEIN, K. SUZUKI, K. HARZER & K. SANDHOFF. 1994. Sphingolipid activator protein D (sap-D) stimulates the lysosomal degradation of ceramide in vivo. Biochem. Biophys. Res. Commun. 200: 1440-1448.
44. Ho, M. W. & J. S. O'BRIEN. 1971. Gaucher's disease: Deficiency of 'acid' t-glucosidase and reconstitution of enzyme activity in vitro. Proc. Natl. Acad. Sci. USA 68: 2810-2813.
45. BIANCO, I. D., G. D. FIDELIO & B. MAGGIO. 1989. Modulation of phospholipase A2 activity by neutral and anionic glycosphingolipids in monolayers. Biochem. J. 258: 95-99.
46. SVENNERHOLM, L. 1994. Gangliosides-A new therapeutic agent against stroke and Alzheimer's disease. Life Sci. 55: 2125-2134.
47. YAMANAKA, S., M. D. JOHNSON, A. GRINBERG, H. WESTPHAL, J. N. CRAWLEY, M. TANIIKE, K. SUZUKI & R. L. PROIA. 1994. Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease. Proc. Natl. Acad. Sci. USA 91: 9975-9979.
48. TANIIKE, M., S. YAMANAKA, R. L. PROIA, C. LANGAMAN, T. BONE-TURENTINE & K. SUZUKI. 1995. Neuropathology of mice with targeted disruption of Hexa gene, a model of TaySachs disease. Acta Neuropathol. 89: 296-304.
49. SANGO, K., S. YAMANAKA, A. HOFFMANN, Y. OKUDA, A. GRINBERG, H. WESTPHAL, M. P. MCDONALD, J. N. CRAWLEY, K. SANDHOFF, K. SUZUKI & R. L. PROIA. 1995. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nature Genet. 11: 170-176.
50. SANGO, K., M. P. MCUONALD, J. N. CRAWLEY, M. L. MACK, C. J. TIFFT, E. SKOP, C. M. STARR, A. HOFFMANN, K. SANDHOFF, K. SUZUKI & R. L. PROIA. 1996. Mice lacking both subunits of lysosomal t-hexosaminidase display gangliosidosis and mucopolysaccharidosis. Nature Genet. 14: 348-352.
51. Liu, Y, A. HOFFMANN, A. GRINBERG, H. WESTPHAL, M. P. MCDONALD, K. M. MILLER, J. N. CRAWLEY, K. SANDHOFF, K. SUZUKI & R. L. PROIA. 1997. Mouse model of GM2 activator deficiency manifests cerebellar ganglioside storage and motor impairment. Proc. Natl. Acad. Sci. USA 94: 8138-8143.
52. FUJITA, N., K. SUZUKI, M. T. VANIER, B. POPKO, N. MAEDA, A. KLEIN, M. HENSELER, K. SANDHOFF, H. NAKAYASU & K. SUZUKI. 1996. Targeted disruption of the mouse sphingolipid activator protein gene: A complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum. Mol. Genet. 5: 711-725.
53. PLATT, F. M., G. R. NEISES, G. REINKENSMEIER, M. J. TOWNSEND, V. H. PERRY, R. L. PROIA, B. WINCHESTER, R. A. DWEK & T. D. BUTTERS. 1997. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 276: 428-431.